abnormal blood pressure ( 90/60 or 160/100 mmHg)
Many patients wonder whether taking both medications together amplifies resultsand clinical evidence suggests strategic combination therapy may offer meaningful benefits when prescribed appropriately
Treatment of DIO mice with PYYMK-801 and GIPMK-801 did not affect body weight or food intake beyond that of the parent peptide analogues (Extended Data Fig
GLP-1 receptor agonists work by stimulating GLP-1 receptors in the body, which leads to several beneficial effects: Increased insulin secretion: GLP-1 receptor agonists promote insulin release from the pancreas, helping to lower blood sugar levels Reduced glucagon secretion: These medications inhibit the release of glucagon, a hormone that increases blood sugar levels, thereby reducing glucose production Slowed gastric emptying: GLP-1 receptor agonists slow down the emptying of the stomach, leading to increased feelings of fullness and reduced appetite Additionally, tirzepatide, the active ingredient in Mounjaro works on GIP receptors
While semaglutide mimics hormones that regulate hunger and satiety, Topamax influences the nervous system, resulting in a more indirect effect on cravings and appetite. Note: Please do not stop taking Topamax without consulting your doctor and under medical supervision